Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;69(2):291-300.
doi: 10.1002/art.39851.

Phenome-Wide Association Study of Rheumatoid Arthritis Subgroups Identifies Association Between Seronegative Disease and Fibromyalgia

Jayanth Doss  1 , Huan Mo  2 , Robert J Carroll  3 , Leslie J Crofford  3 , Joshua C Denny  3
Affiliations

Phenome-Wide Association Study of Rheumatoid Arthritis Subgroups Identifies Association Between Seronegative Disease and Fibromyalgia

Jayanth Doss et al. Arthritis Rheumatol. 2017 Feb.

Abstract

Objective: The differences between seronegative and seropositive rheumatoid arthritis (RA) have not been widely reported. We performed electronic health record (EHR)-based phenome-wide association studies (PheWAS) to identify disease associations in seropositive and seronegative RA.

Methods: A validated algorithm identified RA subjects from the de-identified version of the Vanderbilt University Medical Center EHR. Serotypes were determined by rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (ACPA) values. We tested EHR-derived phenotypes using PheWAS comparing seropositive RA and seronegative RA, yielding disease associations. PheWAS was also performed in RF-positive versus RF-negative subjects and ACPA-positive versus ACPA-negative subjects. Following PheWAS, select phenotypes were then manually reviewed, and fibromyalgia was specifically evaluated using a validated algorithm.

Results: A total of 2,199 RA individuals with either RF or ACPA testing were identified. Of these, 1,382 patients (63%) were classified as seropositive. Seronegative RA was associated with myalgia and myositis (odds ratio [OR] 2.1, P = 3.7 × 10-10 ) and back pain. A manual review of the health record showed that among subjects coded for Myalgia and Myositis, ∼80% had fibromyalgia. Follow-up with a specific EHR algorithm for fibromyalgia confirmed that seronegative RA was associated with fibromyalgia (OR 1.8, P = 4.0 × 10-6 ). Seropositive RA was associated with chronic airway obstruction (OR 2.2, P = 1.4 × 10-4 ) and tobacco use (OR 2.2, P = 7.0 × 10-4 ).

Conclusion: This PheWAS of RA patients identifies a strong association between seronegativity and fibromyalgia. It also affirms relationships between seropositivity and chronic airway obstruction and between seropositivity and tobacco use. These findings demonstrate the utility of the PheWAS approach to discover novel phenotype associations within different subgroups of a disease.

PubMed Disclaimer

Conflict of interest statement

Disclosures/Conflicts of Interest: Jayanth Doss – None Huan Mo – None Robert Carroll - None Leslie Crofford - None Josh Denny - None

Figures

Figure 1
Figure 1
PheWAS Manhattan plots of rheumatoid arthritis (RA) patients comparing serotypes and serologies. The horizontal red lines designate FDR = 0.05. Downward arrows (▼) represent phenotypes associated with seronegative RA. Upward arrows (▲) represent phenotypes associated with seropositive RA. A. PheWAS Manhattan plot of seropositive vs seronegative RA patients. B. PheWAS Manhattan plot of RF (rheumatoid factor) positive vs RF negative RA patients. C. PheWAS plot of ACPA (anti-citrullinated peptide antibody) positive vs ACPA negative RA patients.
Figure 2
Figure 2
Histogram displaying number of days between first rheumatoid arthritis (RA) diagnostic code and first fibromyalgia diagnostic code. Each bar represents 365 days. Days > 0 denotes number of days RA was coded before fibromyalgia and Days < 0 denotes number of days fibromyalgia was coded before RA.
See this image and copyright information in PMC

Comment in

References

    1. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81. - PubMed
    1. Brigham and Women’s Hospital. BRASS (Brigham and Women’s Hospital Rheuamtoid Arthritis Sequential Study) [Internet] BRASS; 2015. [cited 2015 Jan 6]. Available from: http://www.brassstudy.org/brass-information/overview/
    1. Maehlen MT, Olsen IC, Andreassen BK, Viken MK, Jiang X, Alfredsson L, et al. Genetic risk scores and number of autoantibodies in patients with rheumatoid arthritis. Ann Rheum Dis. 2013 Dec 13; annrheumdis – 2013–204173. - PubMed
    1. Greiner A, Plischke H, Kellner H, Gruber R. Association of Anti-Cyclic Citrullinated Peptide Antibodies, Anti-Citrullin Antibodies, and IgM and IgA Rheumatoid Factors with Serological Parameters of Disease Activity in Rheumatoid Arthritis. Ann N Y Acad Sci. 2005;1050(1):295–303. - PubMed
    1. Raza K, Breese M, Nightingale P, Kumar K, Potter T, Carruthers DM, et al. Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis. J Rheumatol. 2005 Feb 1;32(2):231–8. - PMC - PubMed